23:47 , Aug 1, 2019 |  BC Extra  |  Financial News

Vida seeking bigger deals, cures with $600M fund

As Vida Ventures prepares to deploy its $600 million second fund, the firm believes its larger investments in biotech megarounds can continue to be good bets. Vida, whose team includes several former members of Kite...
15:32 , May 21, 2019 |  BC Extra  |  Company News

Merck bets on HIF2As with Peloton takeout ahead of planned listing

Days before Peloton was to price an IPO that would fund Phase III testing of its HIF2A program to treat kidney cancer, the biotech has elected instead to take a buyout offer from Merck &...
19:54 , May 13, 2019 |  BC Extra  |  Financial News

May 13 Financial Quick Takes: Biotech trio update IPO plans, plus Vedanta, TreeFrog

Peloton, Ideaya, Bicycle set IPO terms  Peloton Therapeutics Inc. (Dallas, Texas) was among three biotechs amending proposed IPOs on NASDAQ. The HIF2A company plans to sell 9.4 million shares at $15-$17. If priced at the...
14:31 , Apr 26, 2019 |  BC Extra  |  Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
23:58 , Apr 4, 2019 |  BC Week In Review  |  Clinical News

Peloton’s PT2977 leads to partial response rate of 22% in RCC patients

Peloton said once-daily 120 mg PT2977 led to a confirmed partial response rate of 22% among 55 evaluable previously treated patients with advanced renal cell carcinoma in the Phase II portion of a Phase I/II...
19:10 , Feb 22, 2019 |  BC Week In Review  |  Financial News

Peloton planning Phase III kidney cancer study with $150M series E

With the proceeds of its new $150 million series E round, Peloton Therapeutics Inc. (Dallas, Texas) plans to start a Phase III trial next half of lead candidate PT2977 to treat advanced renal cell carcinoma...
19:51 , Feb 20, 2019 |  BC Extra  |  Financial News

Peloton planning Phase III kidney cancer study with $150M series E

With the proceeds of its new $150 million series E round, Peloton Therapeutics Inc. (Dallas, Texas) plans to start a Phase III trial next half of lead candidate PT2977 to treat advanced renal cell carcinoma...
22:42 , Sep 21, 2018 |  BioCentury  |  Product Development

Arrowhead refills its quiver

Arrowhead Pharmaceuticals Inc.’s tox blowup in 2016 set back its clinical timelines, but it also prompted the company to bring a more versatile platform online faster than originally planned. Early data from replacement candidates suggest...
00:24 , Jan 24, 2018 |  BC Extra  |  Preclinical News

HIF inhibition could prevent chemo-induced TNBC tumor recurrence

A study published in Proceedings of the National Academy of Sciences suggests combining hypoxia-inducible factor (HIF) inhibitors with chemotherapy could help prevent recurrence of triple-negative breast cancer (TNBC). In the paper, researchers from Johns Hopkins...
16:50 , Oct 17, 2017 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Hepatic Patient sample and mouse studies suggest inhibiting intestinal HIF2A could help treat hepatic steatosis. In distal ileum biopsies from obese individuals, HIF2A levels and serum levels of hepatic toxicity markers were higher than...